- Diet
- Cancer
- Colorectal Cancer
- Prostate Cancer
- Breast Cancer
- Adenoid Cystic Carcinoma
- Amyloidosis
- Anal Cancer
- Appendix Cancer
- Astrocytoma - Childhood
- Ataxia-Telangiectasia
- Beckwith-Wiedemann Syndrome
- Bile Duct Cancer (Cholangiocarcinoma)
- Birt-Hogg-Dubé Syndrome
- Bladder Cancer
- Bone Cancer (Sarcoma of Bone)
- Brain Stem Glioma - Childhood
- Brain Tumor
- Breast Cancer - Inflammatory
- Breast Cancer - Metastatic
- Breast Cancer - Male
- Carney Complex
- Central Nervous System Tumors (Brain and Spinal Cord) - Childhood
- Cervical Cancer
- Childhood Cancer
- Cowden Syndrome
- Craniopharyngioma - Childhood
- Desmoid Tumor
- Desmoplastic Infantile Ganglioglioma, Childhood Tumor
- Ependymoma - Childhood
- Esophageal Cancer
- Ewing Sarcoma - Childhood and Adolescence
- Eye Melanoma
- Eyelid Cancer
- Familial Adenomatous Polyposis
- Familial GIST
- Familial Malignant Melanoma
- Familial Pancreatic Cancer
- Gallbladder Cancer
- Gastrointestinal Stromal Tumor - GIST
- Germ Cell Tumor - Childhood
- Gestational Trophoblastic Disease
- Head and Neck Cancer
- Hereditary Breast and Ovarian Cancer
- Hereditary Diffuse Gastric Cancer
- Hereditary Leiomyomatosis and Renal Cell Cancer
- Hereditary Mixed Polyposis Syndrome
- Hereditary Pancreatitis
- Hereditary Papillary Renal Carcinoma
- HIV/AIDS-Related Cancer
- Juvenile Polyposis Syndrome
- Kidney Cancer
- Laryngeal and Hypopharyngeal Cancer
- Leukemia - Acute Lymphoblastic - ALL - Childhood
- Leukemia - Acute Lymphocytic - ALL
- Leukemia - Acute Myeloid - AML
- Leukemia - Acute Myeloid - AML - Childhood
- Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia
- Leukemia - Chronic Lymphocytic - CLL
- Leukemia - Chronic Myeloid - CML
- Leukemia - Chronic T-Cell Lymphocytic
- Leukemia - Eosinophilic
- Li-Fraumeni Syndrome
- Liver Cancer
- Lung Cancer - Non-Small Cell
- Lung Cancer - Small Cell
- Lymphoma - Hodgkin
- Lymphoma - Hodgkin - Childhood
- Lynch Syndrome
- Lymphoma - Non-Hodgkin - Childhood
- Lymphoma - Non-Hodgkin
- Mastocytosis
- Medulloblastoma - Childhood
- Melanoma
- Meningioma
- Mesothelioma
- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia Type 2
- Multiple Myeloma
- MUTYH (or MYH)-Associated Polyposis
- Myelodysplastic Syndromes - MDS
- Nasal Cavity and Paranasal Sinus Cancer
- Nasopharyngeal Cancer
- Neuroblastoma - Childhood
- Neuroendocrine Tumor of the Gastrointestinal Tract
- Neuroendocrine Tumor of the Lung
- Neuroendocrine Tumor of the Pancreas
- Neuroendocrine Tumors
- Neurofibromatosis Type 1
- Neurofibromatosis Type 2
- Nevoid Basal Cell Carcinoma Syndrome
- Oral and Oropharyngeal Cancer
- Osteosarcoma - Childhood and Adolescence
- Ovarian, Fallopian Tube, and Peritoneal Cancer
- Pancreatic Cancer
- Parathyroid Cancer
- Penile Cancer
- Peutz-Jeghers Syndrome
- Pheochromocytoma and Paraganglioma
- Pituitary Gland Tumor
- Pleuropulmonary Blastoma - Childhood
- Retinoblastoma - Childhood
- Rhabdomyosarcoma - Childhood
- Salivary Gland Cancer
- Sarcoma - Kaposi
- Sarcomas, Soft Tissue
- Skin Cancer (Non-Melanoma)
- Small Bowel Cancer
- Stomach Cancer
- Testicular Cancer
- Thymoma and Thymic Carcinoma
- Thyroid Cancer
- Tuberous Sclerosis Complex
- Unknown Primary
- Uterine Cancer
- Vaginal Cancer
- Von Hippel-Lindau Syndrome
- Vulvar Cancer
- Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
- Werner Syndrome
- Wilms Tumor - Childhood
- Xeroderma Pigmentosum
- Veterans with Cancer
- Insurance and Cancer
- Prayers for Cancer Healing
- Prayers for Cancer Survival
- Pharmacology - Cancer Oncology drugs
- Natural Cures for Cancer
- Cancer Causing Foods
- Cancer Fighting Foods
- Kaposi Sarcoma
- Nausea and Vomiting in Cancer
- Adrenocortical Carcinoma
- Adolescents and Young Adults with Cancer
- Basal Cell Carcinoma of the Skin
- Burkitt Lymphoma
- Pancreatic Cancer
- Pain Management in Cancer
- CBD and Cancer Patients
- Cancer Treatment
- Stoma Bag
- Cancer Bra
- Cancer Wigs
- Lymphedema and Cancer
- Ductal Carcinoma In Situ (DCIS)
- Mouth Cancer
- Pregnancy and Breast Cancer
- Endometrial Cancer
- Heart Tumors, Childhood
- Merkel Cell Carcinoma
- Urethral Cancer
- Cancer in Young Adults
- Exercise and Cancer
- Insurance Denial and Cancer
- Bronchial Tumors
- Colostomy and Cancer
- Tube Feeding and Cancer
- Chronic Myeloproliferative Neoplasms
- Pulmonary Inflammatory Myofibroblastic Tumor
- Cutaneous T-Cell Lymphoma
- Fallopian Tube Cancer
- Breast Prostheses after Mastectomy
- Vascular Tumors
- Urethral cancer
- Music
Thymic Epithelial Tumors,The Expression of PD-L1
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
https://plus.google.com/commun....ities/11546213005465
,
,https://plus.google.com/u/0/+A....lexandrosGSfakianaki
,
https://www.youtube.com/channe....l/UCQH21WX8Qn5YSTKrl
,
https://www.youtube.com/channe....l/UCTREJHxB6yt4Gaqs4
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandrossfakianakis/,
Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors
via BioMed Research International
The incidence of thymic epithelial tumors (TETs) in the Chinese population was much higher than that in the North American population. In clinical treatment, the prognosis of benign tumors after surgical resection was significantly better than that of malignant tumors. Currently, the commonly used clinical indicators for TET staging included Masaoka staging and WHO (2015) pathological criteria; however, the distinction between the benign and malignant tumors and diagnosis is yet to be explored. The current study demonstrated that the expression of PD-L1 in tumor cells was correlated with the degree of TET malignancy. The quantitative analysis of PD-L1 expression in 70 cases of TET tumor samples revealed that the positive rate of PD-L1 expression in types A, AB, B1, and B2 of thymoma (40 cases) was 37.5% (15/40), which was significantly lower than that in type B3 thymoma and thymic carcinoma (76.67%, 30 cases, 23/30) as demonstrated by chi-square test (). In addition, the two methods were analyzed for the quantitative detection of PD-L1 expression. The results from the estimation of transcriptional RNA expression and quantitative protein immunohistochemistry were consistent (). Furthermore, we also analyzed PD-L1 expression level in different types of TETs from TCGA database and observed that higher PD-L1 expression was in thymic carcinoma than in thymoma. Therefore, it could be concluded that PD-L1 expression in TET cells was correlated with the degree of malignancy, whereas the estimation of PD-L1 expression was potentially applicable in the clinical staging of TETs.
Add tags (Currently: BioEngineering, Research, Medicine by Alexandros G. Sfakianakis)
SORT BY-
Top Comments
-
Latest comments